IH vs PG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
iHuman Inc. presents a classic deep-value paradox: it possesses a stable Piotroski F-Score of 6/9 and an exceptionally clean balance sheet, yet it is plagued by severe growth decay. While the stock trades at a significant discount to its Graham Number ($4.08) and book value (P/B 0.61), the negative YoY revenue (-18.10%) and earnings (-33.30%) growth suggest a value trap. The current price of $1.74 is slightly below the growth-based intrinsic value of $1.82, but the bearish technical trend and weak insider sentiment offset the valuation appeal.
PG exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is severely overvalued relative to its deterministic baselines. The current price of $145.71 represents a massive premium over the Graham Number ($58.45) and Intrinsic Value ($47.25), while a PEG ratio of 3.92 indicates the valuation is disconnected from its stagnant growth. Negative earnings growth (-5.40% YoY) combined with bearish insider activity and a 0/100 technical trend suggests significant downside risk despite the company's operational efficiency.
Compare Another Pair
Related Comparisons
IH vs PG: Head-to-Head Comparison
This page compares iHuman Inc. (IH) and The Procter & Gamble Company (PG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.